Clinical Investigation of Corneal Incision Size After Intraocular Lens (IOL) Implantation

NCT ID: NCT02826421

Last Updated: 2018-07-02

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

114 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-07-04

Study Completion Date

2016-11-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare corneal incision size after IOL implantation with the use of one of four IOL delivery systems (three preloaded IOL delivery systems and one manually loaded IOL delivery system).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cataracts

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

UltraSert Preloaded Delivery System

Preloaded IOL delivered via a 2.2 mm clear corneal incision during cataract surgery

Group Type EXPERIMENTAL

UltraSert Preloaded Delivery System

Intervention Type DEVICE

Includes AcrySof IQ monofocal posterior chamber IOL Model AU00T0, intended for long term use over the lifetime of the subject

iTec Preloaded Delivery System

Preloaded IOL delivered via a 2.2 mm clear corneal incision during cataract surgery

Group Type ACTIVE_COMPARATOR

iTec Preloaded Delivery System

Intervention Type DEVICE

Includes TECNIS 1-piece monofocal IOL, intended for long term use over the lifetime of the subject

iSert Preloaded Delivery System

Preloaded IOL delivered via a 2.2 mm clear corneal incision during cataract surgery

Group Type ACTIVE_COMPARATOR

iSert Preloaded Delivery System

Intervention Type DEVICE

Includes Model 251 or Model 250 posterior chamber IOL, as selected by the Investigator, intended for long term use over the lifetime of the subject

Monarch III D Manual IOL Delivery System

Manually loaded IOL delivered via a 2.4 mm clear corneal incision during cataract surgery

Group Type ACTIVE_COMPARATOR

Monarch III D Manual IOL Delivery System

Intervention Type DEVICE

Includes AcrySof IQ monofocal IOL posterior chamber IOL Model SN60WF, intended for long term use over the lifetime of the subject

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

UltraSert Preloaded Delivery System

Includes AcrySof IQ monofocal posterior chamber IOL Model AU00T0, intended for long term use over the lifetime of the subject

Intervention Type DEVICE

iTec Preloaded Delivery System

Includes TECNIS 1-piece monofocal IOL, intended for long term use over the lifetime of the subject

Intervention Type DEVICE

iSert Preloaded Delivery System

Includes Model 251 or Model 250 posterior chamber IOL, as selected by the Investigator, intended for long term use over the lifetime of the subject

Intervention Type DEVICE

Monarch III D Manual IOL Delivery System

Includes AcrySof IQ monofocal IOL posterior chamber IOL Model SN60WF, intended for long term use over the lifetime of the subject

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Able to comprehend and sign a statement of informed consent;
* Willing and able to complete all required postoperative visits;
* Cataract;
* Planned cataract removal by phacoemulsification;
* Calculated lens power from 18.0 through 27.0 D inclusive;
* Preoperative astigmatism \<1.0D;

Exclusion Criteria

* Systemic disease that affects the cornea;
* Any inflammation or edema of the cornea;
* Previous or planned refractive or corneal surgery during the subject's participation in the study;
* Previous corneal transplant;
* Previous retinal detachment;
* Pregnancy or lactation, current or planned, during the course of the study;
* Current participation in another investigational drug or device study that may confound the results of this investigation;
* Any condition observed before or during surgery that in the surgeon's medical opinion may affect the success of the cataract surgery;
Minimum Eligible Age

22 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Alcon Research

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sr. Clinical Manager, GCRA

Role: STUDY_DIRECTOR

Alcon Research

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ILN296-P001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Cataract Surgery Clinical Trial
NCT07044674 WITHDRAWN NA